U.S. markets closed

Recro Pharma, Inc. (REPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9200-0.0500 (-2.54%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.9700
Open2.0000
Bid1.9000 x 800
Ask2.0000 x 3100
Day's Range1.9000 - 2.0000
52 Week Range1.4900 - 5.2900
Volume397,698
Avg. Volume540,995
Market Cap89.01M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-1.0510
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Recro Appoints Erica Raether as Vice President of People, Culture and ESG
    GlobeNewswire

    Recro Appoints Erica Raether as Vice President of People, Culture and ESG

    Innovative Human Resources Executive with Deep Expertise Developing and Implementing People-Focused Strategies to Support Employee Engagement, Advance ESG Objectives and Achieve Operational GoalsEXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the appointm

  • Recro Enters Development and Manufacturing Agreement With New Client
    GlobeNewswire

    Recro Enters Development and Manufacturing Agreement With New Client

    GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client. Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the c

  • All You Need to Know About Recro Pharma (REPH) Rating Upgrade to Buy
    Zacks

    All You Need to Know About Recro Pharma (REPH) Rating Upgrade to Buy

    Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).